The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Neuraminidase Inhibitors for Influenza
Abstract
he impact of influenza infection is felt globally each year when the disease develops in approximately 20 percent of the world’s population. In the United States, influenza infections occur in epidemics each winter, generally between late December and early March. Recent events, including human cases of avian influenza, have heightened awareness of the threat of a pandemic and have spurred efforts to develop plans for its control. Although vaccination is the primary strategy for the prevention of influenza, there are a number of likely scenarios for which vaccination is inadequate and effective antiviral agents would be of the utmost importance. During any influenza season, antigenic drift in the virus may occur after formulation of the year’s vaccine has taken place, rendering the vaccine less protective, and outbreaks can more easily occur among highrisk populations. In the course of a pandemic, vaccine supplies would be inadequate. Vaccine production by current methods cannot be carried out with the speed required to halt the progress of a new strain of influenza virus; therefore, it is likely that vaccine would not be available for the first wave of spread of virus. 1 Antiviral agents thus form an important part of a rational approach to epidemic influenza and are critical to planning for a pandemic. Four drugs are currently available for the treatment or prophylaxis of influenza infections: the adamantanes (amantadine and rimantadine) and the newer class of neuraminidase inhibitors (zanamivir [Relenza] and oseltamivir [Tamiflu]). The adamantanes interfere with viral uncoating inside the cell. They are effective only against influenza A and are associated with several toxic effects and with rapid emergence of drug-resistant variants. Adamantane-resistant isolates of influenza A are genetically stable, can be transmitted to susceptible contacts, are as pathogenic as wild-type virus isolates, and can be shed for prolonged periods in immunocompromised patients taking the drug. This potential for the development of resistance especially limits the use of the adamantanes for the treatment of influenza, although the drugs still have a place in planning for prophylaxis during an epidemic. The neuraminidase inhibitors zanamivir and oseltamivir interfere with the release of progeny influenza virus from infected host cells, a process that prevents infection of new host cells and thereby halts the spread of infection in the respiratory tract (Fig. 1). Since replication of influenza virus in the respiratory tract reaches its peak between 24 and 72 hours after the onset of the illness, drugs such as the neuraminidase inhibitors that act at the stage of viral replication must be administered as early as possible. In contrast to the adamantanes, the neuraminidase inhibitors are associated with very little toxicity and are far less likely to promote the development of drug-resistant influenza. As a class, the neuraminidase inhibitors are effective against all neuraminidase subtypes t
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
(2002) · PsycEXTRA Dataset · doi:10.1037/e548512006-001 · Cited by 1,708
Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia
Li, K. S., Guan, Y., Wang, J., Smith, G. J. D., Xu, K. M., Duan, L., Rahardjo, A. P., Puthavathana, P., Buranathai, C., Nguyen, T. D., et al. (2004) · Nature · doi:10.1038/nature02746 · Cited by 1,343
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Probable Person-to-Person Transmission of Avian Influenza A (H5N1)
Ungchusak, K., Auewarakul, P., Dowell, S. F., Kitphati, R., Auwanit, W., Puthavathana, P., Uiprasertkul, M., Boonnak, K., Pittayawonganon, C., Cox, N. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044021 · Cited by 869
Structure of the catalytic and antigenic sites in influenza virus neuraminidase
Colman, P. M., Varghese, J. N., & Laver, W. G. (1983) · Nature · doi:10.1038/303041a0 · Cited by 798
Transmissibility of 1918 pandemic influenza
Mills, C. E., Robins, J. M., & Lipsitch, M. (2004) · Nature · doi:10.1038/nature03063 · Cited by 796
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Clinical signs and symptoms predicting influenza infection
Monto, A. S., Gravenstein, S., Elliott, M., Colopy, M., & Schweinle, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3243 · Cited by 752
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A., & Klenk, H.-D. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12665-12667.2004 · Cited by 606
Cox, N. J., & Subbarao, K. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01241-6 · Cited by 586
Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., & Straus, S. E. (1999) · JAMA · doi:10.1001/jama.282.13.1240 · Cited by 550
Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., & Mills, R. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411802 · Cited by 512
Kaiser, L., Wat, C., Mills, T., Mahoney, P., Ward, P., & Hayden, F. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1667 · Cited by 501
Welliver, R. (2001) · JAMA · doi:10.1001/jama.285.6.748 · Cited by 463
Early administration of oral oseltamivir increases the benefits of influenza treatment
Aoki, F. Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg007 · Cited by 424
Varghese, J. N., McKimm‐Breschkin, J. L., Caldwell, J. B., Kortt, A. A., & Colman, P. M. (1992) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340140302 · Cited by 402
Role of Neuraminidase in Lethal Synergism between Influenza Virus and Streptococcus pneumoniae
McCullers, J. A., & Bartmess, K. C. (2003) · The Journal of Infectious Diseases · doi:10.1086/368163 · Cited by 386
Inhaled Zanamivir for the Prevention of Influenza in Families
Hayden, F. G., Gubareva, L. V., Monto, A. S., Klein, T. C., Elliott, M. J., Hammond, J. M., Sharp, S. J., & Ossi, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431801 · Cited by 371
Cooper, N. J., Sutton, A. J., Abrams, K. R., Wailoo, A., Turner, D., & Nicholson, K. G. (2003) · BMJ · doi:10.1136/bmj.326.7401.1235 · Cited by 357
(1998) · The Lancet · doi:10.1016/s0140-6736(98)10190-3 · Cited by 351
Hayden, F. G., Belshe, R., Villanueva, C., Lanno, R., Hughes, C., Small, I., Dutkowski, R., Ward, P., & Carr, J. (2004) · The Journal of Infectious Diseases · doi:10.1086/381128 · Cited by 334
Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, Jr., Elliott, M. J., & Crisp, A. (1999) · JAMA · doi:10.1001/jama.282.1.31 · Cited by 321
Influenza Viruses Resistant to the Antiviral Drug Oseltamivir: Transmission Studies in Ferrets
Herlocher, M. L., Truscon, R., Elias, S., Yen, H., Roberts, N. A., Ohmit, S. E., & Monto, A. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/424572 · Cited by 292
McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., & Zambon, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2264-2272.2003 · Cited by 291
Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Meindl, P., Bodo, G., Palese, P., Schulman, J., & Tuppy, H. (1974) · Virology · doi:10.1016/0042-6822(74)90080-4 · Cited by 287
Monto, A. S., Fleming, D. M., Henry, D., de Groot, R., Makela, M., Klein, T., Elliott, M., Keene, O. N., & Man, C. Y. (1999) · The Journal of Infectious Diseases · doi:10.1086/314904 · Cited by 275
HEDRICK, J. A., BARZILAI, A., BEHRE, U., HENDERSON, F. W., HAMMOND, J., REILLY, L., & KEENE, O. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200005000-00005 · Cited by 245
Varghese, J. N., Chandana Epa, V., & Colman, P. M. (1995) · Protein Science · doi:10.1002/pro.5560040606 · Cited by 199
Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population
Peters, P. H., Gravenstein, S., Norwood, P., De Bock, V., Van Couter, A., Gibbens, M., Von Planta, T., & Ward, P. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49204.x · Cited by 190
Mäkelä, M. J., Pauksens, K., Rostila, T., Fleming, D. M., Man, C. Y., Keene, O. N., & Webster, A. (2000) · Journal of Infection · doi:10.1053/jinf.1999.0602 · Cited by 180
Leneva, I. A., Roberts, N., Govorkova, E. A., Goloubeva, O. G., & Webster, R. G. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00123-6 · Cited by 167
Position statement: global neuraminidase inhibitor susceptibility network
Zambon, M. C. F. A., & Hayden, F. G. (2001) · Antiviral Research · doi:10.1016/s0166-3542(01)00124-3 · Cited by 155
Monto, A. S., Pichichero, M. E., Blanckenberg, S. J., Ruuskanen, O., Cooper, C., Fleming, D., & Kerr, C. (2002) · The Journal of Infectious Diseases · doi:10.1086/345722 · Cited by 148
Use of Oseltamivir During Influenza Outbreaks in Ontario Nursing Homes, 1999–2000
Bowles, S. K., Lee, W., Simor, A. E., Vearncombe, M., Loeb, M. B., Tamblyn, S. E., Fearon, M. A., Li, Y., McGeer, A., & The Oseltamivir Compassionate Use Program Group (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50153.x · Cited by 143
The Threat of an Avian Influenza Pandemic
Monto, A. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048343 · Cited by 135
Pharmacoscintigraphic Evaluation of Lung Deposition of Inhaled Zanamivir in Healthy Volunteers
Cass, L., Brown, J., Pickford, M., Fayinka, S. T., Newman, S. P., Johansson, C. J., & Bye, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936001-00003 · Cited by 132
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus
Tumpey, T. M., García‐Sastre, A., Mikulasova, A., Taubenberger, J. K., Swayne, D. E., Palese, P., & Basler, C. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212519699 · Cited by 127
Detection and Control of Influenza Outbreaks in Well-Vaccinated Nursing Home Populations
Monto, A. S., Rotthoff, J. R., Teich, E., Herlocher, M. L., Truscon, R., Yen, H., Elias, S., & Ohmit, S. E. (2004) · Clinical Infectious Diseases · doi:10.1086/422646 · Cited by 123
Palese, P., Schulman, J. L., Bodo, G., & Meindl, P. (1974) · Virology · doi:10.1016/0042-6822(74)90458-9 · Cited by 113
Perspectives on antiviral use during pandemic influenza
Hayden, F. G. (2001) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2001.1007 · Cited by 109
Rapid diagnostic tests for influenza
Storch, G. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200302000-00013 · Cited by 106
Murphy, K. R., Eivindson, A., Pauksens, K., Stein, W. J., Tellier, G., Watts, R. W., ophonte, P. L., Sharp, S. J., & Loeschel, E. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200020050-00005 · Cited by 105
Freund, B., Gravenstein, S., Elliott, M. J., & Miller, I. A. (1999) · Drug Safety · doi:10.2165/00002018-199921040-00003 · Cited by 105
Avian Influenza and Pandemics — Research Needs and Opportunities
Stöhr, K. (2005) · New England Journal of Medicine · doi:10.1056/nejme048344 · Cited by 97
Kawai, N., Ikematsu, H., Iwaki, N., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/429241 · Cited by 92
Prevention of influenza in the general population
Langley, J. M., & Faughnan, M. E. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031737 · Cited by 72
Ленева, И. А., Goloubeva, O. G., Fenton, R. J., Tisdale, M., & Webster, R. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1216-1224.2001 · Cited by 61
Pandemic Influenza: Is an Antiviral Response Realistic?
Hayden, F. G. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000144680.39895.ce · Cited by 54
Matsumoto, K., Ogawa, N., Nerome, K., Numazaki, Y., Kawakami, Y., Shirato, K., Arakawa, M., Kudoh, S., Shimokata, K., Nakajima, S., et al. (1999) · Antiviral Therapy · doi:10.1177/135965359900400202 · Cited by 52
Oseltamivir-resistant influenza?
Moscona, A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16947-x · Cited by 50
Self-citationMatsumoto, K., Ogawa, N., Nerome, K., Numazaki, Y., Kawakami, Y., Shirato, K., Arakawa, M., Kudoh, S., Shimokata, K., Nakajima, S., et al. (1999) · PubMed · Cited by 47
Tackling the next influenza pandemic
Balicer, R. D., Huerta, M., & Grotto, I. (2004) · BMJ · doi:10.1136/bmj.328.7453.1391 · Cited by 22
OXFORD, J. S., Balasingam, S., & Lambkin, R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh037 · Cited by 20
Cited by
Mitigation strategies for pandemic influenza in the United States
Germann, T. C., Kadau, K., Longini, I. M., & Macken, C. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601266103 · Cited by 1,047
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Newhouse, T., Baran, P. S., & Hoffmann, R. W. (2009) · Chemical Society Reviews · doi:10.1039/b821200g · Cited by 807
Antiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance
Bloom, J. D., Gong, L. I., & Baltimore, D. (2010) · Science · doi:10.1126/science.1187816 · Cited by 649
Metadata
- Authors
- Moscona, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-29
- Volume
- 353
- Issue
- 13
- Pages
- 1363-1373
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2104397822
- Cited by
- 1,094
- References
- 59
- FWCI
- 44.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.